




PHARMACEUTICAL 2020

JOHNSON & JOHNSON
Rank 171 of 358





RealRate

PHARMACEUTICAL 2020

JOHNSON & JOHNSON Rank 171 of 358



The relative strengths and weaknesses of JOHNSON & JOHNSON are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of JOHNSON & JOHNSON compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 86% points. The greatest weakness of JOHNSON & JOHNSON is the variable Assets, Current, reducing the Economic Capital Ratio by 60% points.

The company's Economic Capital Ratio, given in the ranking table, is 91%, being 55% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	45,274,000
Cost of Goods Sold	27,556,000
Intangible Assets	81,282,000
Liabilities, Current	35,964,000
Liabilities, Non-Current	38,228,000
Other Assets	13,514,000
Other Compr. Net Income	-669,000
Other Expenses	3,683,000
Other Liabilities	24,065,000
Other Net Income	-2,168,000
Other Revenues	82,059,000
Property and Equipment	17,658,000
Research and Development	11,355,000
Selling, General and Administrative Expense	22,178,000

Output Variable	Value in 1000 USD
Assets	157,728,000
Liabilities	98,257,000
Expenses	64,772,000
Revenues	82,059,000
Stockholders Equity	59,471,000
Net Income	15,119,000
Comprehensive Net Income	14,784,500
Economic Capital Ratio	91%